{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:55:44Z","timestamp":1762498544973,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.euf.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T06:44:11Z","timestamp":1542869051000},"page":"1006-1012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria"],"prefix":"10.1016","volume":"6","author":[{"given":"Jeffrey P.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egbert A.","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian Vinter","family":"Juul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.11.001_bib0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.juro.2010.04.011","article-title":"The prevalence and causes of nocturia","volume":"184","author":"Bosch","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.11.001_bib0010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.12688\/f1000research.11979.1","article-title":"Nocturia: consequences, classification, and management","volume":"6","author":"Fine","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.euf.2018.11.001_bib0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.smrv.2010.03.002","article-title":"The effect of nocturia on sleep","volume":"15","author":"Ancoli-Israel","year":"2011","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.euf.2018.11.001_bib0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/nau.20484","article-title":"Nocturia: etiology, diagnosis, and treatment","volume":"27","author":"Appell","year":"2008","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.11.001_bib0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1464-410X.2011.10175.x","article-title":"The evaluation and treatment of nocturia: a consensus statement","volume":"108","author":"Weiss","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.11.001_bib0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4111\/kju.2013.54.8.492","article-title":"Current evaluation and treatment of nocturia","volume":"54","author":"Park","year":"2013","journal-title":"Korean J Urol"},{"key":"10.1016\/j.euf.2018.11.001_bib0035","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.juro.2011.05.083","article-title":"Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia","volume":"186","author":"Weiss","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.11.001_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/luts.12169","article-title":"Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study","volume":"10","author":"Rover","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2018.11.001_bib0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/978-3-642-16499-6_21","article-title":"Vasopressin receptors in voiding dysfunction","volume":"202","author":"Pisipati","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.euf.2018.11.001_bib0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/nau.22243","article-title":"Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Weiss","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.11.001_bib0055","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.juro.2012.12.112","article-title":"Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study","volume":"190","author":"Weiss","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.11.001_bib0060","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.juro.2013.02.037","article-title":"Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study","volume":"190","author":"Sand","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.11.001_bib0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2288-9-55","article-title":"A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder","volume":"9","author":"Lee","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euf.2018.11.001_bib0070","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/j.1464-410X.2010.09972.x","article-title":"Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant?","volume":"107","author":"Smith","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.11.001_bib0075","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/2229-3485.154016","article-title":"Common pitfalls in statistical analysis: P values, statistical significance and confidence intervals","volume":"6","author":"Ranganathan","year":"2015","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.euf.2018.11.001_bib0080","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.urology.2015.02.043","article-title":"Nocturia: current levels of evidence and recommendations from the international consultation on male lower urinary tract symptoms","volume":"85","author":"Marshall","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.euf.2018.11.001_bib0085","unstructured":"Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC). FDA briefing document. October 19, 2016. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM525329.pdf."},{"key":"10.1016\/j.euf.2018.11.001_bib0090","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2009.03.080","article-title":"Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland","volume":"57","author":"Tikkinen","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.11.001_bib0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.eururo.2007.01.027","article-title":"Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study","volume":"52","author":"van Kerrebroeck","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.11.001_bib0100","unstructured":"Noctiva (desmopressin acetate) nasal spray. Summary review for regulatory action. September 04, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/summary_review\/2017\/201656Orig1s000SumR.pdf."},{"key":"10.1016\/j.euf.2018.11.001_bib0105","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1464-410X.2012.11547.x","article-title":"Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial","volume":"111","author":"Yamaguchi","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.11.001_bib0110","doi-asserted-by":"crossref","first-page":"F1116","DOI":"10.1152\/ajprenal.00741.2010","article-title":"Gender difference in antidiuretic response to desmopressin","volume":"300","author":"Juul","year":"2011","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545691830333X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545691830333X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:51:35Z","timestamp":1762498295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545691830333X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S240545691830333X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.11.001","relation":{},"ISSN":["2405-4569"],"issn-type":[{"type":"print","value":"2405-4569"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}